MEI Pharma, Inc.

MEI Pharma, Inc. said on 22 July that its board of directors unanimously agreed to hire a financial consultant that can help the company assess strategic alternatives to maximize the value of its ass

History has not been kind to PI3K inhibitors, but Scorpion Therapeutics, Inc. hopes that its mutant-selective PI3Kα inhibitor, STX-478, can do what most drugs in the class have not, which is show th

SELLAS Life Sciences Group, Inc. is in a strong position in acute myeloid leukemia (AML) with positive data from a Phase IIa study of SLS009 and the completion of enrollment in its Phase III trial of

Cost-cutting has become the norm for biopharmaceutical companies in 2023 as drug developers struggle to raise capital for ongoing research and development programs, never mind bringing in new funding